Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

IMPORTANCE: Tumor mutational burden (TMB), as measured by whole-exome sequencing (WES) or a cancer gene panel (CGP), is associated with immunotherapy responses. However, whether TMB estimated by circulating tumor DNA in blood (bTMB) is associated with clinical outcomes of immunotherapy remains to be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Wang, Zhijie, Duan, Jianchun, Cai, Shangli, Han, Miao, Dong, Hua, Zhao, Jun, Zhu, Bo, Wang, Shuhang, Zhuo, Minglei, Sun, Jianguo, Wang, Qiming, Bai, Hua, Han, Jiefei, Tian, Yanhua, Lu, Jing, Xu, Tongfu, Zhao, Xiaochen, Wang, Guoqiang, Cao, Xinkai, Li, Fugen, Wang, Dalei, Chen, Yuejun, Bai, Yuezong, Zhao, Jing, Zhao, Zhengyi, Zhang, Yuzi, Xiong, Lei, He, Jie, Gao, Shugeng, Wang, Jie
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512308/
https://ncbi.nlm.nih.gov/pubmed/30816954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.7098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados